Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 28, Issue 30, Pages 4609-4615
Publisher
American Society of Clinical Oncology (ASCO)
Online
2010-09-21
DOI
10.1200/jco.2010.30.5474
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors
- (2010) Faye M. Johnson et al. CANCER
- Epidermal Growth Factor Receptor cooperates with Src Family Kinases in acquired resistance to cetuximab
- (2010) Deric L. Wheeler et al. CANCER BIOLOGY & THERAPY
- Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non–Small-Cell Lung Cancer
- (2010) Eric B. Haura et al. JOURNAL OF CLINICAL ONCOLOGY
- The Src Inhibitor AZD0530 Blocks Invasion and May Act as a Radiosensitizer in Lung Cancer Cells
- (2010) Phillip R. Purnell et al. Journal of Thoracic Oncology
- A Phase II Study of Dasatinib in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30602)
- (2010) Antonius A. Miller et al. Journal of Thoracic Oncology
- A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
- (2010) Jiannong Li et al. Nature Chemical Biology
- Sustained Src Inhibition Results in Signal Transducer and Activator of Transcription 3 (STAT3) Activation and Cancer Cell Survival via Altered Janus-Activated Kinase-STAT3 Binding
- (2009) B. Sen et al. CANCER RESEARCH
- Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)- Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors
- (2009) U. McDermott et al. CANCER RESEARCH
- Synergistic Activity of the Src Family Kinase Inhibitor Dasatinib and Oxaliplatin in Colon Carcinoma Cells Is Mediated by Oxidative Stress
- (2009) S. Kopetz et al. CANCER RESEARCH
- Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
- (2009) G. D. Demetri et al. CLINICAL CANCER RESEARCH
- EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases
- (2009) K. Schmid et al. CLINICAL CANCER RESEARCH
- Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions
- (2009) Martin L. Sos et al. JOURNAL OF CLINICAL INVESTIGATION
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
- (2009) R. L. Wahl et al. JOURNAL OF NUCLEAR MEDICINE
- Src Promotes Survival and Invasion of Lung Cancers with Epidermal Growth Factor Receptor Abnormalities and Is a Potential Candidate for Molecular-Targeted Therapy
- (2009) E. L.-H. Leung et al. MOLECULAR CANCER RESEARCH
- Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin
- (2009) P. Ceppi et al. MOLECULAR CANCER THERAPEUTICS
- Src kinases as therapeutic targets for cancer
- (2009) Lori C. Kim et al. Nature Reviews Clinical Oncology
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More